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Abstract
At present, only the United States and New Zealand allow direct-to-consumer advertising
(DTCA) of prescription medicine. In other countries where DTCA is not allowed, including
Australia and the United Kingdom, pharmaceutical companies undertake disease awareness
advertising (DAA). In DAA, advertisements do not name a drug directly, but provide general
information about diseases and treatments, and encourage consumers to talk to their doctor.
Similar debate surrounds these two forms of advertising, yet while past research has explored
consumers’ attitudes and behaviour in response to DTCA, little consideration has been given
to DAA. This paper compares Australian consumers’ perceptions of DAA with New Zealand
consumers’ perceptions of DTCA. Despite differences in the type and extent of advertising,
respondents perceived similar benefits including heightened awareness of treatment options
and improved discussions with doctors. New Zealand respondents associated many negative
outcomes with DTCA including unbalanced information, inappropriate requests to doctors
and consumer confusion.

Introduction
Direct to consumer advertising (DTCA) occurs when pharmaceutical companies promote
prescription medicine brands to the general public, via mass media or other media including
the Internet. An alternative, disease awareness advertising (DAA), occurs when
pharmaceutical companies or other organizations (including the government and non-profit
organizations) promote diseases or conditions, rather than named treatments (ANZTPA,
2005). Pharmaceutical companies use DAA to promote diseases or conditions for which they
produce a treatment, and typically do so in jurisdictions where DTCA is prohibited (Mintzes,
2006).
DTCA is currently legal in only two countries within the Organization for Economic
Cooperation and Development (OECD), the United States (US) and New Zealand. There is
on-going debate in both countries about the benefits of DTCA, growing concern about the
potential harms it may cause (Toop et al., 2003; Moynihan and Bay, 2007), and speculation
about its future (Royne and Myers, 2008). Other countries, including Canada, European
Union and Australia, have considered introducing DTCA, and it remains a topical regulatory
question in many countries (Gardner et al., 2003; Toop and Mangin, 2006, 2007).
Questions about the benefits delivered by DTCA have focused attention on its origins and
effects. Mandese (2005) suggested that the key beneficiaries of DTCA were media and
advertising groups, both of which played important roles in its introduction, and have lobbied
for more relaxed regulatory oversight. However, Donohue (2006) suggested DTCA had its
genesis in the patients’ rights movement of the 1970s where it reflected a change from the
‘learned intermediary’ model of healthcare to a partnership model. She suggested that DTCA
capitalizes on consumers’ desire for empowerment, a point recognized by pharmaceutical
companies, which have funded patient advocacy groups (Jacobson, 2005). Yet, while DTCA

provides information, its profit motive continues to trouble medical and social researchers
(Coney, 2002).
Proponents of DTCA argue that it educates consumers about new medicines and the diseases
these treat (Bonaccorso and Sturchio, 2002; Auton, 2004, 2007). Other benefits thought to
accrue from DTCA include earlier diagnosis, more informed discussions with doctors, and
increased compliance with treatment regimens (Auton, 2007). Recent studies suggest that
DTCA also provides information to groups with lower health literacy, and so may help
reduce health inequities (Kaphingst et al., 2005). However, Mintzes (2002) concludes that
DTCA may mislead consumers by inflating the likely benefits they will receive from taking a
treatment and downplaying the risks and side effects. Toop et al. (2003) extend this point and
argue that DTCA creates an over-reliance on medications when behavioural or lifestyle
changes may achieve better long-term outcomes. DTCA may not only promote less optimal
treatment paths, but Toop and Mangin (2006) also suggest it may damage doctor–patient
relationships by stimulating requests for advertised drugs that do not suit patients’ overall
health profile. They conclude that the difficulty of dealing with poorly informed requests
could reduce the high level of trust required between doctors and patients and result in
misallocation of consultation time.
In many countries where DTCA is not permitted, consumers are exposed to pharmaceutical
company-sponsored DAA, which is designed to create awareness of diseases and the
availability of treatments. For DAA, a similar debate over its ethics and effects has occurred
(Glatter, 2004; Mintzes, 2006). Moynihan and Henry (2006) argue that, like DTCA, DAA
will encourage healthy people to believe they may require potentially unnecessary tests or
medication. In some instances, such as when a new treatment becomes available,
pharmaceutical companies attempt to partner with disease support groups to undertake
advertising and public relations activities. However, this can have negative implications if the

risk profile of the treatment is not fully known, and because the advertising is portrayed as a
community service its commercial intent is obscured (Mackenzie et al., 2007). For example
in 2000, the Arthritis Foundation encouraged arthritis sufferers to ask their doctors about an
exciting new treatment via a community service announcement on the only Australian noncommercial television channel. This promotion occurred following a donation of $250 000 to
the Arthritis Foundation by the makers of Celebrex (Searle and Pfizer) (Barry, 2000), but
prior to the risks associated with cox-2 inhibitors being exposed.
In other instances, pharmaceutical companies have been criticized for providing unbalanced
information or exaggerating the prevalence or severity of a condition which may cause
consumer anxiety and unnecessary visits to their doctor (Mintzes, 2006; Hall and Jones,
2007; Hall, 2008). For example, one of a series of advertisements in Canada (produced by the
manufacturers of a cholesterol-lowering medication) depicted a young, healthy man about to
walk around the corner into the charge of a rhinoceros. The tagline for the advertisements
was ‘Living with high cholesterol, you never know what’s around the corner’. The text
describes the risk of death from heart attack, and while cholesterol is discussed, other risk
factors (such as smoking, obesity and blood pressure) are omitted (Mintzes, 2006). The use of
fear appeals in pro-social advertising has been criticized as they have been found to induce
maladaptive responses such as chronic anxiety for those most at risk, or complacency for
those not directly targeted (Hastings et al., 2004).
There is concern that DAA circumvents the ban on DTCA because, while it does not include
the name of a prescription medicine product, it often contains other branding techniques such
as the use of logos or spokes-characters to communicate the identity of a product (such as the
Pfizer tiger character used to promote Viagra). Further, DAA targeting consumers often
coincides with branded promotions targeting medical professionals (Glatter, 2004; Hall and
Jones, 2007).

In contrast, proponents argue that DAA educates consumers about diseases and conditions,
enables them to keep up to date with new treatments, and encourages those who are
potentially at risk to visit their doctor (Wielondek, 2005; Angelmar et al., 2007). These
arguments clearly reflect themes evident in the long-running debate over DTCA and raise
questions about consumers’ perceptions of these different forms of pharmaceutical
advertising. The current study examined Australian and New Zealand consumers’ perceptions
of DAA and DTCA, respectively. The findings provide the first insights into how consumers
respond to DAA, enable a comparison of consumers’ perceptions of DAAand DTCA, and
may help to inform regulatory decisions about pharmaceutical promotions facing many
developed nations.

Advertising expenditure and media exposure
Glatter (2004) suggests DTCA offers potential returns to manufacturers and Toop et al.
(2003) recorded sharp spikes in prescriptions following DTCA campaigns. The US
Government Accountability Office (GAO) reported a trend of increasing expenditure on
DTCA. Although promotion to physicians still outweighed spending on DTCA, television
and magazine DTCA increased at twice the rate of detailing to doctors during the 1997–2005
period (US GAO, 2006). However, more recent data have indicated a slight drop in U.S.
spend on DTCA between 2006 and 2007 ($US4.81 billion to $US4.77 billion) (IMS Health,
2008). New Zealand data reflect these patterns; pharmaceutical companies spent an estimated
$NZ38 million ($US30.5 million) on DTCA in 2006; this represented the largest category of
advertising spending on therapeutic products (Ministry of Health, 2006a) and was a 217%
increase on the $NZ17.5 million spent on DTCA in 1999.
Growth in expenditure on DTCA has been paralleled by an increase in consumer awareness.

A recent US poll reported that 91% of respondents had heard or seen prescription drug
advertisements (USA Today et al., 2008). Exposure occurs predominantly via television,
which remains the dominant DTCA medium, although print media are also important
(Brownfield et al., 2004; Hoek et al., 2004; Frosch et al., 2007). Wijesinghe and Norris
(2008) reported that the frequency of medicine advertisements during 4 PM to 8 PM on New
Zealand television in 2001 and 2006 had increased from 0.72 advertisements per hour to 1.14
advertisements per hour. DTCA promotions declined as a proportion of medicine
advertisements from 28% in 2001 to 17% in 2006, although this appears to reflect an increase
in the number of over-the-counter (OTC) and complementary medicine promotions.
In 2006, pharmaceutical companies in Australia spent an estimated $AUD190–200 million on
mass media advertising (Nielsen Media Research AdEx, 2006); however, it is difficult to
ascertain how much of this was spent on DAA as this figure includes OTC advertising. In
Europe, it was estimated that spending on DAA would grow to $US345.5 million in 2008
(Mintzes, 2006).
Despite the limited literature on consumers’ responses to DAA, there is some evidence that
this advertising increases awareness of the advertised health conditions and prescriptions of
the sponsor’s product (Basara, 1996; t’Jong et al., 2004). A recent content analysis examined
the prevalence of DAA in top circulating Australian women’s magazines and concluded it
constituted approximately 12% of all therapeutic advertisements (Hall et al., 2009); this
finding suggests its potential exposure is at least moderate.

Regulation
The US Food and Drug Administration (FDA) regulates and oversees DTCA. The FDA has
an explicit ‘fair balance’ criterion that requires information about a drug’s benefits be
balanced by information about its potential risks and side effects (Hoek et al., 2004). Despite

this criterion, recent content analyses have questioned whether this balance is achieved,
particularly in television advertisements (Kaphingst et al., 2004; Macias et al., 2007), and the
GAO had doubts about the adequacy of consumer protection FDA regulation afforded (US
GAO, 2006).
Critics of the US regulatory model suggest self-regulation is more efficient than government
regulation and makes no demands on taxpayer funds (Calfee, 2002). New Zealand relies on
such a system and the advertising industry is responsible for developing codes of practice and
administering the complaints body that adjudicates complaints (Hoek and Gendall, 2002).
The New Zealand system evolved rapidly in response to concerns raised by politicians and
health professionals following DTCA’s emergence in the late 1980s, and rapid growth during
the late 1990s. Following the development of a self-regulatory code, the Advertising
Standards Authority devised a pre-vetting system to improve compliance with the code.
Complaints about all advertising can be made to the Advertising Standards Complaints
Board, which adjudicates these (Advertising Standards Authority New Zealand, 2008).
Despite these measures, DTCA has generated considerable concern and leading health
professionals called on the New Zealand Minister of Health to review the regulatory lacunae
that enabled DTCA to flourish. Two reviews conducted by the New Zealand Ministry for
Health (Ministry of Health, 2000, 2006a) received polarized submissions. In the 2006
Review, submissions by advertising and pharmaceutical industries favoured retaining DTCA
under a liberal self-regulatory system. However, the majority of submitters supported a
complete ban on DTCA because they felt there was inconclusive evidence that DTCA
provides a public health benefit, and that purported benefits were outweighed by potential
harms (Ministry of Health, 2006b). The majority of submitters were concerned that DTCA
led to consumer confusion, and many expressed the need to provide balanced and
independent health information. Submitters also supported removal of for-profit disease-state

advertising as many felt there was little difference between this and DTCA, and that disease
advertising allowed companies to promote products in a less transparent way (Ministry of
Health, 2006b).
In Australia, the Therapeutic Goods Act prohibits advertising of prescription medicines
directly to consumers (Australian Government Department of Health and Ageing, 2007).
However, the development of a Trans-Tasman regulatory scheme for therapeutic products
with New Zealand (the Australian New Zealand Therapeutic Products Authority or
ANZTPA) led to speculation that Australia would allow DTCA, although this has not yet
eventuated. Currently, Australian pharmaceutical companies target consumers via DAA and
unbranded product advertisements, neither of which include the brand name of the
prescription medicine indicated for the disease or health condition (Hall and Jones, 2007).
Medicines Australia, an industry body, monitors this advertising and provides a complaints
service, but does not vet or otherwise restrict placement of DAA (Medicines Australia, 2009).
The fact that pharmaceutical advertising has emerged in different guises, is subject to
different regulatory systems, and yet stimulates similar debate, suggests that further research
exploring consumers’ perceptions of pharmaceutical promotions would provide regulators
with a more robust evidence base to inform their decisions. The following section reviews
existing evidence on US and New Zealand consumers’ views of DTCA.

Consumer perceptions
Existing research suggests US and New Zealand consumers hold generally positive attitudes
toward DTCA and believe it provides them with useful information about health conditions
and treatments, and facilitates discussions with doctors (Mehta and Purvis, 2003; Deshpande
et al., 2004; Hoek et al., 2004). However, consumers are more ambivalent about the overall
worth of DTCA, particularly its role in improving the decisions they make about their health

(Hoek et al., 2004; USA Today et al., 2008). Recent surveys in the US have found growing
negative attitudes towards DTCA, including a dislike of advertisement content and the
perceived ubiquity of DTCA (Friedman and Gould, 2007a; USA Today et al., 2008).
A US survey of 1695 adults found that 67% of respondents felt DTCA provided education
about treatments and encouraged people to seek help for conditions or diseases about which
they had been previously unaware (USA Today et al., 2008). These findings are generally
similar to those reported in New Zealand, where a survey of 625 residents found that 91%
believed DTCA helped make people aware of new medicines (Hoek et al., 2004). Between
half and two thirds of New Zealand respondents found DTCA useful (61%), and thought it
helped people have better discussions with their doctors (64%); however, only half felt it
helped people to make better decisions about their health (52%).
Friedman and Gould (2007a) surveyed 321 US residents and reported high awareness of
DTCA (96%), but noted some negativity towards it; over half reported that they disliked
seeing advertisements for prescription drugs. Nevertheless, 59% still agreed that, overall,
DTCA was a good thing (Friedman and Gould, 2007a). In a USA Today survey, 53% of
adults thought prescription drug advertising was a good thing, however 68% felt that DTCA
appeared too frequently on television and 66% felt it encouraged people to take medications
that they did not really need (USA Today et al., 2008).
Studies of more specific population groups have reported similar findings. DeLorme et al.
(2007) conducted in-depth interviews with older Americans (n=25) to explore their views of
DTCA. While these participants thought DTCA affected others more than themselves, they
nevertheless paid attention to DTCA, and believed it helped them learn about drug benefits
and risks, and assisted them to locate further information. However, they noted that DTCA
lacked balance, portrayed unrealistic outcomes and created pressure on viewers to talk with

their doctors. Respondents also complained about the quantity and frequency of DTCA
(DeLorme et al., 2007).
Because DTCA does not exist in Australia, work exploring consumers’ likely responses has
been hypothetical. Miller and Waller (2004) surveyed 619 individuals and reported that 53%
felt DTCA would provide useful information while 58% felt it would make the public more
aware of the benefits prescription medicines could offer (Miller and Waller, 2004). However,
only 32% agreed that it was proper for prescription medicines to be advertised, and almost
half (48%) felt that DTCA would not improve the quality of prescription medicines available
in the future (Miller and Waller, 2004). These findings are consistent with Vatjanapukka and
Waryszak (2004) who reported mixed responses to DTCA, particularly among those more
knowledgeable about prescription medicines. Jones and Mullan’s (2006) analysis of older
Australians’ views also concluded that participants held ambivalent views about DTCA;
while they recognized it could inform their discussions with doctors, they also thought it
could be confusing and promote reliance on medications.

Current Study
Till date, no studies have compared whether consumers exposed to DTCA differ in their
perceptions and behaviours from those exposed to DAA. This omission is serious, since
global trade and economic alliances are becoming more prevalent and assume a high level of
regulatory congruence. New Zealand and Australia have close economic relations and their
governments have actively promoted stronger trade relationships. Advertising of prescription
medicines in both countries is self-regulated via industry codes of conduct and a complaints
process (Advertising Standards Authority New Zealand, 2009; Medicines Australia, 2009).
Despite their physical proximity, New Zealand and Australia have very little cross-border
advertising, thus the media environments are largely insulated from each other.

The current study examined Australian and New Zealand consumers’ general perceptions of
DAA and DTCA, respectively, and determined perceived benefits or weaknesses of these
advertising formats. The natural experiment created by New Zealand and Australia’s
differing stance on DTCA enables development of an evidence base that may be useful for
countries currently reviewing their position on prescription pharmaceutical advertising, such
as Canada and Europe.

Methodology
The Australian survey questionnaire was conducted in 2006 and questions were based on
surveys previously developed and tested by Hoek et al. (2004) and Hoek and Gendall (2004)
to elicit consumer responses to DTCA in New Zealand in 2002 and 2003, respectively. The
New Zealand questionnaire was part of a broader survey conducted in 2006 to examine New
Zealanders’ views on advertising and how this should be regulated. The questions relating to
prescription medicine were based on those previously used by Hoek et al. (2004) and Hoek
and Gendall (2004). Although both surveys were based on existing instruments, there were
minor differences in the question wording and the scales used.
The Australian sampling frame was a purchased database of mail addresses for a
metropolitan area in New South Wales. A total of 2800 addresses were randomly sampled,
and a pretest was administered randomly to 400 of these addresses. The pretest resulted in 56
responses (response rate of 14%), following which minor modifications were made to the
wording of one question. The remaining 2400 addresses were sent the revised survey
questionnaire.
The New Zealand sample were 2000 people randomly selected from the electoral roll
(registration to vote is mandatory in New Zealand, thus the electoral roll is a comprehensive
database of adults aged 18 years and over).

Results
For the Australian survey, a total of 357 surveys were returned (representing a response rate
of 15%); all responses were used along with those from the pretest, resulting in a total of 413
responses. For the New Zealand survey, a total of 998 respondents completed and returned
their survey (after deducting ineligible and gone-no-address returns, this represents a valid
response rate of 56%). Data from both surveys were weighted so the samples’ age–sex
distributions matched census data; the Australian data matched the metropolitan area from
which the sample was drawn and is similar to the national age–gender profile, while the NZ
data matched the national age–gender profile. The following section reports on Australian
and New Zealand consumers’ perceptions of DAA and DTCA, respectively.

Australian perceptions of DAA
Australian participants were asked whether they agreed or disagreed with nine general
statements about DAA (see Table 1) on a five-point agree–disagree scale. Agree and strongly
agree responses were aggregated. Most respondents (80%) agreed that DAA makes people
aware of disease/conditions and different treatment options and almost two thirds agreed that
DAA helps people to have better discussions with their doctors. While 62% agreed that DAA
is designed to increase positive health behaviours such as diet and exercise, some respondents
may have considered government public health and non-government sponsored
advertisements as well as those sponsored by pharmaceutical companies; thus this estimate
may be higher than if respondents had considered only pharmaceutical company sponsored
DAA. Just over half (52%) felt that DAA helps them to make better decisions about their
health.

Table 1 Australian responses to statements regarding DAA
Statements

% Agreement
(inc. strongly
Agree

+

agree)
(n=413)
Advertisements help make people aware of disease/conditions and different 80
treatment options
Advertisements alert people to disease in order to sell more medicine or 72
medical products
Advertisements about diseases/conditions help people have better 65
discussions with their doctor
Advertisements alert people to disease in order to increase positive health 62
behaviours such
as diet or exercise
Advertisements about diseases/conditions help people make better decisions 52
about their health
Advertisements alert people to disease in order to make the disease itself 43
more important
Advertisements alert people to disease in order to increase visits to doctors 40
or other
health professionals
Advertisements about diseases/conditions confuse people about what 36
disease they may be
at risk of developing
Advertisements about diseases/conditions are often difficult to understand

26

When considering DAA’s intent, 72.2% agreed that this advertising was designed to sell
more medicine or medical products, and around 40% agreed that it was to make the disease
itself seem more important or to increase visits to doctors. Over a third (36%) felt that DAA
confuses people about what diseases they may be at risk of developing, while just over one

quarter (26%) felt that advertisements about diseases and conditions are often difficult to
understand.

New Zealand perceptions of DTCA
To explore respondents’ views on DTCA, New Zealand participants were asked the extent to
which they agreed or disagreed with 11 general statements (see Table 2) on a four point
agree–disagree scale. Agree and strongly agree responses were aggregated. Most respondents
(84%) agreed that DTCA overemphasizes drug benefits and most thought DTCA does not
provide balanced information about the risks and benefits of the medicine. Half agreed that
people probably feel confused by the information given in DTCA. The majority (78%)
believed that prescription medicine advertising makes people more aware of options to treat
their health problems; however, over 80% considered that most people lack the technical
knowledge required to tell whether an advertised medicine is safe for them. Nearly two thirds
agreed that advertising for prescription medicines helps people have more informed
discussions with their doctor; however, a similar proportion thought DTCA leads people to
ask their doctor for medicines that may not suit them. Over half believed that DTCA makes
people rely more on medicines to treat their health conditions, though only 12% thought it
harms the relationship that patients have with their doctor.
Sixty per cent of New Zealand respondents agreed that it would be better to spend the money
that is used to regulate prescription medicine advertising on a neutral information service.
There was a strong preference for a government agency to manage regulation of prescription
medicine advertising (33%), followed by an independent group (15%), the advertisers and the
media (6%) and just under a fifth (17%) of New Zealand respondents thought that the
advertising of prescription medicines should not be allowed; the remainder were either unsure

(8%) or in favour of a combination of a government agency, independent group and
advertisers and the media to manage prescription medicine advertising (21%).

Discussion
Despite the differences in the questions and scales of the surveys conducted in either country,
as well as differences in the types of pharmaceutical advertising, there are several similarities
between the Australian and New Zealand results.

Generating awareness
Very similar proportions of both samples agreed that the purpose of DAA and DTCA is to
make people aware of health conditions and treatment options. These findings are similar to
US surveys, which reported high levels of agreement with the proposition that DTCA helps
increase awareness of options or new medicines (Hoek et al., 2004; USA Today et al., 2008).
Similar proportions of Australian and New Zealand respondents reported feeling informed
about treatment options, irrespective of whether they saw DAA or DTCA. This suggests that
in Australia, even unbranded promotions create high levels of treatment awareness.

Table 2 New Zealand responses to statements regarding DTCA
Statements

% Agreement
(inc. strongly
Agree + agree)
(n=998)

Prescription medicine advertisements over-emphasize the benefits and do 83
not explain the risks enough
Most people lack the technical knowledge to tell whether an advertised 81
medicine is safe
Advertising for prescription medicines makes people more aware of 77

options that could treat
their health problems
Advertising for prescription medicines leads people to ask their doctor for 67
medicines that may not be suitable
Advertising for prescription medicines helps people have more informed 64
discussions with their doctor
It would be better if money spent on regulating prescription medicine 60
advertising was used to provide a neutral information service
Advertising for prescription medicines makes people rely more on 54
medicines to treat health conditions
Most people probably understand the information in advertisements for 48
prescription medicines
Most people probably feel confused by the information in advertisements 47
for prescription medicines
Prescription medicine advertisements provide balanced information about 26
a medicine’s risks and benefits
Advertising for prescription medicines harms the relationship patients 12
have with doctors

Health decisions and health behaviour
Australians exposed to DAA were ambivalent about whether these advertisements help them
to make better health decisions, which is similar to results relating to DTCA from earlier New
Zealand and US consumer surveys (see Hoek et al., 2004). More recent findings suggest
views towards DTCA as an information source have become more negative in the US; for
example, Friedman and Gould (2007a) reported that only 41% of their respondents agreed
that DTCA helped them to make better decisions about their health (Friedman and Gould,
2007a). Furthermore, only 19% of physicians thought DTCA assisted their patients to make
better health decisions (Friedman and Gould, 2007b).
While the results revealed some similar patterns, important differences were also evident. For
example, while 55% of New Zealand respondents felt that DTCA makes people rely more on

medicines to treat medical conditions, 62% of Australian respondents felt that DAA is
designed to increase other positive health behaviours such as diet and exercise. Although
New Zealand respondents were not asked about the potential lifestyle benefits that DTCA
might promote, the proportion who felt DTCA offered a ‘pill for every ill’ suggests fewer
would be likely to agree that DTCA brought wider benefits. Only 40% of Australian
respondents felt that DAA was designed to encourage consumers to visit a doctor or health
professional, even though Medicines Australia stipulates that this information must be
included in DAA (Medicines Australia, 2009). A high proportion of New Zealand
respondents agreed that DTCA would prompt consumers to ask for drugs that may not suit
them. This implies that studies examining the influence of pharmaceutical promotions on
interactions with health professionals should also explore the types of requests that would be
made and the likely health benefits that would ensue.

Interaction with doctor
The majority of respondents in both countries (65%) agreed that pharmaceutical advertising
improves discussions with their doctor. These proportions are similar to those reported in
earlier New Zealand surveys, which in turn are very similar to US survey results. Just under
two thirds of respondents in these countries (64% New Zealand and 61% US) felt that DTCA
helps people to have better discussions with their doctor about their health (Hoek et al.,
2004). Murray et al. (2004) surveyed 3209 US residents and found DTCA encourages
patients to disclose health concerns to their doctors and helps some to feel more confident
and in control of their consultation. While studies into US physicians’ attitudes concur that
DTCA may help patients to initiate discussions with their doctor (Murray et al., 2003;
Weissman et al., 2004), Friedman and Gould (2007b) found only 27% of the 416 physicians

they surveyed felt DTCA gave patients adequate information to decide whether to discuss a
drug with their doctor.
Over two-thirds of the New Zealand respondents (68%) felt DTCA led to requests to doctors
for medicines that may not be appropriate, an identical finding to the 2008 USA Today poll.
Studies of US physicians’ attitudes have found that around 80% felt DTCA led to
inappropriate requests for unnecessary prescriptions (Friedman and Gould, 2007b; Weissman
et al., 2004). Toop et al. (2006) argue that responding to such requests and re-educating
patients can detract from valuable consultation time; this problem requires further research to
assess whether other adverse outcomes result. Twelve per cent of New Zealand respondents
agreed that DTCA harms the doctor–patient relationship; this is a higher proportion than
Murray et al. (2004) reported; their US work estimated that only 5% of respondents who took
DTCA information to their doctors thought this had negatively affected their relationship.

Consumer understanding of advertising
Nearly three quarters of Australian respondents (72%) agreed that DAA aimed to sell more
treatments (or medical products). These results imply Australians are aware that DAA has a
profit motive and may allay concerns that consumers falsely perceive DAA to be a
community service. However, further research is required to determine how Australian
consumers respond to actual DAA with varying sponsors before these concerns can be put
aside. Similar research could be undertaken in New Zealand, particularly given that 60% of
respondents felt resources spent on regulating DTCA could be better spent providing neutral
drug information.
With regard to the confusion caused by advertisements, 48% of New Zealand respondents
thought that most people felt confused by the information in DTCA. In contrast, 36% of
Australian respondents felt that DAA confused people about the disease they may be at risk

of developing. However, New Zealand respondents were almost twice as likely to report
difficulties in understanding DTCA (49%) than Australians (26%). This result may reflect the
more detailed product information required in DTCA, which includes technical details that
lay people are unlikely to understand; this interpretation is supported by the finding that 81%
of New Zealand respondents agreed most people lacked the technical knowledge to judge the
safety of an advertised product.
These findings are supported by previous studies identifying the potential of pharmaceutical
promotions to mislead or confuse consumers (Kaphingst and DeJong, 2004; Jones and
Mullan, 2006). Our findings also support earlier recommendations to improve DTCA,
including requiring a more effective balance of risk and benefit information (Kaphingst et al.,
2004) and presenting important risk information in a stand-out window format (Stotka et al.,
2007). Use of more quantitative data to support benefit claims and reducing emotional
appeals that suggest a disease is more prevalent or a drug more efficacious than is really the
case would also help to increase the ease with which lay consumers understand DTCA
(Woloshin et al., 2001; Woloshin and Schwartz, 2006). Finally, the use of consumer friendly
language is recommended to promote understanding and reduce the demands on doctors
(Handlin et al., 2003; Kaphingst et al., 2004).

Limitations
A significant limitation of the Australian survey is the low response rate, which may result in
a level of non-response bias. Another limitation previously mentioned is that Australian
respondents may have considered government or non-government sponsored DAA or even
OTC advertising when responding to the questions regarding DAA, and thus responses
specific to pharmaceutical company sponsored DAA for prescription medicines may differ.
The two surveys used different sampling methods, different measurement scales and different

questions; however, as the purpose of the research was to compare general perceptions of
DAA and DTCA, the questions needed to reflect the different regulatory environments and
the data were suitable for comparisons outlined.

Conclusion and Future Research
Australian and New Zealand consumers value DAA and DTCA for generating awareness of
disease and treatment options and improving discussions with their doctors. Overall,
Australian consumers found DAA less confusing than New Zealanders found DTCA,
although further work is required to test how exposure to DAA and DTCA, respectively,
influences consumers’ understanding and knowledge. Respondents were ambivalent about
whether pharmaceutical advertising improved their decision making and a neutral
information service may be a more effective means of improving their knowledge of diseases
and treatment options.
An area of growing interest is healthcare websites, with a Nielsen online custom survey in
2008 finding more than 80% of internet users seek healthcare information online and report
high levels of trust in the written content of websites (The Nielsen Company, 2010). The
presence of pharmaceutical company-sponsored disease awareness websites appears to be
increasing, and a recent study of Australian general practitioners found that close to half had
recommended such websites to their patients after receiving incentives or enticements from
pharmaceutical companies (Usher and Skinner, 2009). There is concern regarding health
information on the internet as searches for common symptoms can result in consumers
experiencing considerable anxiety and unnecessarily engaging health professionals (White
and Horvitz, 2009). ‘Cyberchondria’ is defined as ‘the unfounded escalation of concerns
about common symptomatology, based on the review of search results and literature on the
Web’ (White and Horvitz, 2009: p. 23:2). Further research should consider whether

pharmaceutical company websites increase cyberchondria and medicalization, as well as
consumer demand for pharmacological treatments.
For DAA and DTCA, benchmark studies are needed into consumer responses to these
different forms of advertising to determine how they influence consumers’ behaviour and
public health outcomes. From this, longitudinal studies could more accurately measure the
influence of advertising and differing advertising regulation to better inform future health
policy. Future work examining information credibility, the trust respondents place in different
sources, and the likelihood they would use information from these, will also be important as
decisions regarding the adoption and continuation of DAA and DTCA are made. Perhaps
most critically, however, future research should also locate consumers’ views within the
broader ethical and economic debate over prescription medicine promotions and the optimal
means of providing consumers with information that is in their best interests.
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